

Announcement Summary

Entity name

IMMUTEP LIMITED

Announcement Type

New announcement

Date of this announcement

26/7/2021

The Proposed issue is:

C A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
IMM	ORDINARY FULLY PAID	88,970,717

Proposed +issue date

30/7/2021

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

IMMUTEP LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

Registration Number 009237889

1.3 ASX issuer code

IMM

ACN

1.4 The announcement is

Solution New announcement

1.5 Date of this announcement

26/7/2021

1.6 The Proposed issue is:

C A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1a Conditions

Approval/ConditionDate for determinationIs the date estimated or
actual?** Approval
received/condition met?+Security holder approval26/7/2021© ActualYes

Comments

The proposed issue of 88,970,717 Tranche 2 New Shares was approved at the Extraordinary General Meeting held on Monday, 26 July 2021.

Part 7B - Issue details

Will the proposed issue of this +security include an offer of attaching +securities? ☑ No

Details of +securities proposed to be issued

ASX +security code and description IMM : ORDINARY FULLY PAID

Number of +securities proposed to be issued

88,970,717

Offer price details

In what currency is the cash

What is the issue price per



consideration being paid?

AUD - Australian Dollar

+security? AUD 0.52000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? C Yes

7C.1 Proposed +issue date 30/7/2021

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? C Yes

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

26/7/2021

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? C No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? 🕑 No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? 🕑 No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue? C Yes

7E.1a Who is the lead manager/broker?

Bell Potter Australia Pty Ltd and Jefferies Australia Pty Ltd are the Joint Lead Managers.



7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

In respect of the Placement, the Joint Lead Managers will be paid a fee of 5% of the proceeds received by the Company under the Placement and will also be reimbursed for certain eligible expenses.

7E.2 Is the proposed issue to be underwritten? 𝔅 No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

No other material fees or costs to be incurred.

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

The funds will be used for further development and expansion of the Company's current and future product pipeline of LAG-3 candidates for the treatment of cancer and autoimmune diseases, and for working capital purposes.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No

7F.2 Any other information the entity wishes to provide about the proposed issue

Information on the Placement are contained in an announcement released to ASX on 21 June 2021.

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:
☑ The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)